Event Abstract Back to Event PPAR-γ agonist pioglitazone exerts its neuroprotective activity in reserpine induced Parkinson-depression triads by evaluating the endoplasmic reticulum stress markers and inflammatory cytokine levels in rat brain Sahabuddin Ahmed1*, Nityanand Bolshette2, Mohit Kwatra1, Anwaruddin Ahmed3 and Yogita Sharma1 1 National Institute of Pharmaceutical Education and Research-Guwahati, Laboratory of Neuroscience,Department of Pharmacology and Toxicology, India 2 National Institute of Pharmaceutical Education and Research-Guwahati, Institutional Biotech Hub, India 3 Rajarajeshwari Medical College and Hospital, Department of Pathology, India Parkinson disease (PD) is the second most common neurodegenerative disease characterized by progressive loses of dopaminergic neurons in the substantia nigra. The cause of PD is still unclear but aging, environmental factors, oxidative stress, neuro inflammation and genetic factors may be involved in the progression of this disease. Animal models are widely used to study alternations caused by PD. The biochemical and cellular changes that occurs following repeated dose of reserpine (0.1 mg/kg body weight every alternate day for 20 days) a monoamine depleting agent, mimics similar to those seen in PD. Peroxisome proliferator-activated receptor (PPAR) are ligand-activated transcription factors of the nuclear hormone receptor superfamily. PPAR-γ is widely expressed in the CNS whose activation causes downregulation of proinflammatory cascades associated with acute and chronic neurological insults. Therefore we examined the efficacy of the PPAR-γ agonist Pioglitazone in rodent model of PD. The major mechanism through which Pioglitazone exerts its neuroprotection seems to prevention of microglial activation, halting of inflammatory cytokines, decreasing chemokines expression and also by preventing the oxidative stress damage. Pioglitazone at a dose of 10 mg/kg body weight when given to reserpinsed rats for last 14 days of the treatment causes remarkable changes in the behavior parameters. Moreover we try to co-relate this disease with depression. On the 22nd day animals were sacrificed and specific region of brain were isolated mainly the hippocampus and cortex and were assessed for various antioxidant enzymes level. Inflammatory cytokine (IL-1ß,NF-κß,TNF-α,IL-6) levels were evaluated. ER stress markers namely GRP-78 (78 kDa-glucose-regulated protein) and CCAAT/enhancer binding protein homologous protein CHOP/GADD153 levels were significantly diminishes on Pioglitazone treatment. Our results reveal that clinical treatment with Pioglitazone, a FDA-approved drug may offer a treatment opportunity in PD by slowing its progression. Keywords: Brain, transcription factor, Parkinson’s disease, neurodegeneration, in vivo Conference: 14th Meeting of the Asian-Pacific Society for Neurochemistry, Kuala Lumpur, Malaysia, 27 Aug - 30 Aug, 2016. Presentation Type: Poster Presentation Session Topic: 14th Meeting of the Asian-Pacific Society for Neurochemistry Citation: Ahmed S, Bolshette N, Kwatra M, Ahmed A and Sharma Y (2016). PPAR-γ agonist pioglitazone exerts its neuroprotective activity in reserpine induced Parkinson-depression triads by evaluating the endoplasmic reticulum stress markers and inflammatory cytokine levels in rat brain. Conference Abstract: 14th Meeting of the Asian-Pacific Society for Neurochemistry. doi: 10.3389/conf.fncel.2016.36.00209 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 04 Aug 2016; Published Online: 11 Aug 2016. * Correspondence: Mr. Sahabuddin Ahmed, National Institute of Pharmaceutical Education and Research-Guwahati, Laboratory of Neuroscience,Department of Pharmacology and Toxicology, Guwahati, Assam, India, sahabuddin.ahmed@yale.edu Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Sahabuddin Ahmed Nityanand Bolshette Mohit Kwatra Anwaruddin Ahmed Yogita Sharma Google Sahabuddin Ahmed Nityanand Bolshette Mohit Kwatra Anwaruddin Ahmed Yogita Sharma Google Scholar Sahabuddin Ahmed Nityanand Bolshette Mohit Kwatra Anwaruddin Ahmed Yogita Sharma PubMed Sahabuddin Ahmed Nityanand Bolshette Mohit Kwatra Anwaruddin Ahmed Yogita Sharma Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.